New startup ideas · Health and bio · Healthcare and bio

startup idea

Bayworks

Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.

Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.

Marketplace
Enterprise
$100B+ market
Creates a new category
US first

5/5

venture judge

similar startups, last 2 years (8 all-time)

96%

of 3 nearest real companies still alive

yes

8 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$4,100 · 6 weeks · 20 prospects

For $4,100 in 6 weeks, prove that clinical-stage cell therapy CMC leads will sign dated LOIs for batch slots in a hospital-hosted bay that does not exist, and that regulators plausibly allow one qualified bay to serve multiple sponsors' filings.

Riskiest assumption · A CMC lead at a clinical-stage cell therapy sponsor will sign a dated commitment for batch slots in a hospital-hosted bay qualified by a third party they have never audited, rather than waiting in a known CDMO's queue.

1Focus group: who and where

The head of CMC or manufacturing at a US clinical-stage cell therapy sponsor with a phase 1 or 2 trial running, who is staring at a 12-18 month CDMO slot queue or a multi-year suite reservation quote that exceeds their remaining runway.

where to find 20 · ClinicalTrials.gov filtered for active US phase 1-2 CAR-T and autologous cell therapy trials, which yields a named sponsor list with real capacity pressure; the Alliance for Regenerative Medicine member directory and ISCT community for both sponsors and hospital GMP facility directors; Meeting on the Mesa in October in Phoenix, the one conference where cell therapy CMC leads and academic medical center facility heads are in the same hallway; plus warm introductions through biotech investors and advisors for the first five calls.

2Sell first, build later

Four reserved manufacturing slots in the first Bayworks bay at a named academic medical center, qualified by Bayworks and added to the sponsor's filing, target start Q3 2027, with slot scheduling priority over all later signers.

the ask · $60,000 per batch indicative, plus a booking fee at MSA signing; the LOI itself carries no payment

a real yes · A real yes is a signed LOI with a dated Q3 2027 start and a named quality contact, or a hospital MOU naming a specific suite. Conference enthusiasm, 'keep us posted' emails, and unsigned verbal interest are not yeses.

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Fifteen CMC capacity calls
$200 · 14 days
Build a 40-sponsor list from ClinicalTrials.gov and the ARM directory, open with warm intros where they exist, and book 15 calls with CMC or manufacturing heads. Ask for their 2027 batch forecast, current CDMO queue time, cost per batch, and whether a third-party-qualified bay could pass their quality team.
keep going if · 8 of 15 name a dated capacity gap in the next 12 months and say a Bayworks-qualified bay would enter their quality review, not be rejected outright
2. Regulatory fungibility check
$1,500 · 10 days
Buy three one-hour consultations with former CBER reviewers or CMC regulatory consultants found through the Regulatory Affairs Professionals Society, and put the kill question to each: can one bay, qualified once, be referenced by multiple sponsors' filings without full sponsor-specific re-inspection, and under what mechanism. This is the stated risk tested for $1,500 instead of two years.
keep going if · 2 of 3 consultants describe a workable referencing path and its conditions, rather than saying per-sponsor full inspection is unavoidable
3. LOI slot sale
$500 · 21 days
Draft a one-page LOI with light counsel review: 4 reserved batch slots in the first bay at a named partner academic medical center, target start Q3 2027, indicative $60,000 per batch, named quality contacts on both sides. Offer it to the 8 warmest sponsors from the calls and negotiate to signature.
keep going if · 2 of 8 sponsors sign the LOI with a dated start and a named quality contact
4. Hospital supply-side MOU
$1,900 · 21 days
At Meeting on the Mesa and through ISCT contacts, hold 5 conversations with GMP facility directors at academic medical centers about monetizing underused suite hours on a revenue share, and push the best one to a signed MOU naming the suite and the split. One founder attends the conference; the trip is the cost.
keep going if · 1 academic medical center signs an MOU naming a specific underused suite and a revenue share

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

no cash yet: take a signed commitment

how · No money changes hands: a clinical-stage sponsor cannot credibly prepay for capacity in an unbuilt, unregistered bay, and their quality system forbids it before an audit. Collect instead a signed LOI with a dated start, batch count, and named quality contact, signed by the CMC head, and on the supply side a hospital MOU naming the suite and revenue share, signed by the facility director.

what it reserves · First-cohort slot priority in the first qualified bay, the $60,000 indicative batch price, and a named place in the bay's initial qualification plan

refund · The LOI is non-binding on price and volume and either side may withdraw in writing before the master services agreement is signed.

target · 2 signed dated LOIs from 8 offers and 1 hospital MOU within 42 days

before taking money · Do not describe any bay as GMP, take booking fees, or run a batch before FDA facility registration and the hospital quality agreement are in place; keep every commitment a non-binding LOI or MOU reviewed by regulatory counsel.

Go: build it if

2+ signed LOIs with dated Q3 2027 starts, 1 hospital MOU naming a suite, and 2 of 3 regulatory consultants confirming a multi-sponsor referencing path: demand, supply, and regulatory feasibility all have signatures, so raise the capital round against them.

Kill: stop if

0 LOIs from 8 offers, no hospital willing to name a suite, or 2 of 3 consultants saying full sponsor-specific inspection per bay is unavoidable: the fungibility the marketplace depends on does not exist and the business is a regional CDMO at best, so stop.

5 Scripts to run itoutreach message, landing copy, deposit terms · click to open

outreach message

You are heading CMC on a per-patient therapy, which means every new trial site raises the same question: where does the dose get made, and how many months does the slot take. I am qualifying standardized GMP bays inside hospital systems and selling capacity by the batch instead of by the multi-year suite reservation. Before building the first bay I am pressure-testing the model with 15 CMC leads. Can I get 20 minutes this week to walk through your 2027 capacity plan?

landing page

GMP batch slots near your patients, booked in weeks Reserve 4 slots at $60,000 per batch indicative, first bay live Q3 2027, held by a signed LOI Request the LOI and slot schedule

deposit terms

This LOI reserves 4 production slots in the first Bayworks bay at our partner academic medical center, target start Q3 2027, at an indicative $60,000 per batch. It is non-binding on price and volume but carries a dated start and named quality contacts on both sides. No payment is due until the bay passes your quality audit and a master services agreement is signed.

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 59.0 x 1.61

Warm

competition: more crowded than 32% of ideas · headwind x0.84

+3.4

government priorities, secondary (28 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)61
Rounds announced 2025+ in the sector68
Sector direction (live batch)100
2026 trend analyst25

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)75
Operator judge: real pain50

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge100
Market size axis100
Moat axis80
Neighbours still alive81
Technologist judge75

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were licensed, gmp, manufacturing, bays, personalized, therapies, sold, bookable.

The idea in full

What: Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations. Each bay is qualified once by Bayworks and then added to a sponsor's filing as a licensed site, so a sponsor with a per-patient therapy can add capacity near the patient in weeks rather than building its own plant. Enterprise pharma and clinical-stage biotech pay a booking fee plus per-batch run fees; hospital and CDMO partners take a share of the slot revenue.
Why now: The current YC batches are full of per-patient biologics that cannot use conventional batch plants: Gamgee on scalable personalised cancer treatment, RonanRx Inc. personalizing peptides to individual biology, TareBio promising vaccines for any cancer or infection in weeks, and FinalDose on programmable DNA drugs; meanwhile Ambrosia Biosciences raised a $100M Series B on 2026-03-31, which is the size of check that goes into physical capacity.
Wedge: first customer and entry point: One academic medical center with an underused GMP suite plus three clinical-stage cell therapy sponsors: qualify a single bay, sell twenty booked batches, and use that filing package as the template for every subsequent bay.
Path to 100x: Biologics and cell and gene manufacturing is a $100B+ spend that is currently sold as bespoke long-term contracts, and turning it into bookable, pre-licensed capacity creates a category the way cloud compute did for servers. Every qualified bay makes the next sponsor faster to onboard, and the accumulated regulatory filings and site licenses are the moat, because a competitor must repeat inspection and qualification bay by bay.
Ceiling: If personalized therapies stay in small trials, total booked batch volume stays too low to fill the capital-heavy bay network and the business settles into being a regional CDMO.
Closest real companies, as the generator saw them: AbInitio Bio sells an intelligence layer for drug manufacturing as software, while Bayworks owns the licensed physical bay and the booking transaction. Ruma Care runs the operations stack for biologic infusion clinics at the delivery end; Bayworks sits one step upstream, at the point where the dose is made.
Main risk: Regulators treat each bay as a distinct site requiring full sponsor-specific inspection, which kills the fungibility the marketplace depends on.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
5/5
Pre-qualified bays turn a $100B+ bespoke contract market into bookable capacity, and each accumulated FDA filing compounds into a moat competitors must rebuild bay by bay.
Bootstrapper
1/5
Building FDA-registered cleanroom bays inside hospitals is nine figures of capital and per-site inspection before a single batch fee lands.
Operator
3/5
Sponsors already pay for suite reservations, but the whole thesis needs regulators to treat a qualified bay as fungible across filings.
Technologist
4/5
Qualifying a bay once and porting that filing package to each sponsor is years of regulatory engineering no weekend clone reproduces.
Risk
3/5
Owns its FDA site licences, but the stated risk is real: sponsor-specific inspection per bay makes the marketplace's fungibility a single regulatory assumption.
trends
2/5
The per-patient therapy manufacturing crunch is real but was known in 2023, and bookable GMP capacity needs no 2025-2026 trigger to exist.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (licensed, gmp, manufacturing, bays, personalized, therapies, sold, bookable): 8 all-time, 1 from the last two years. Same matching as Idea Check.

RonanRx Inc.yc S26 · 2026 · Healthcare and bioalive
Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s
Jiminispc · 2024 · Healthcare and bioalive
AI-assisted behavioral health
Finni Healthef EF Toronto 2022 · 2022 · Healthcare and bioalive
Nationwide virtual ABA therapy for autism.
Perception Biosystemsyc S18 · 2018 · Robotics and physical worldsite down
Democratizing gene therapy by reinventing its manufacturing and…
3DPrinterOSalchemist Alchemist Class 7 · 2014 · Robotics and physical worldunchecked
In Your Corneryc S14 · 2014 · Healthcare and biosite down
We've transformed traditional therapy into an experience that is…
OrthoSens SAplugandplay · Healthcare and bioalive
OrthoSens provides battery-free sensors that implant manufacturers embed directly into their standard implants, turning them into a connected, data-generating and recurring revenue asset
株式会社シンプロジェンplugandplay · Healthcare and bioalive
Synplogen is a company that brings together unique DNA synthesis technologies that Kobe University and others have been developing.

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1327

startup-relevant grants in Healthcare and bio

$703M

awarded in the sector, tracked

127

opportunities open now in the sector

Role of nanoparticle mediated drug delivery in preventing arteriovenous fistula stenosisawardhigh relevance
NIH / NIDDK · SBIR phase II · $1M · posted 2026-09-02
Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure and cancer adjuvant therapyawardhigh relevance
NIH / NCATS · SBIR phase II · $986K · posted 2026-07-01
Multiplexed Hormone Test for Personalizing Menopause Treatmentawardhigh relevance
NIH / NICHD · SBIR phase I · $301K · posted 2025-09-15
Development of a Non-Addictive Intranasal Nerve Block to Provide Rapid Acute Treatment for Headache Disordersawardhigh relevance
NIH / NINDS · SBIR phase II · $1M · posted 2026-09-03
Long-term formulation for combination antiviral treatment of HIVawardhigh relevance
NIH / NIAID · SBIR phase I · $307K · posted 2026-09-01
Injectable Hydrogel Treatment for Hidradenitis Suppurativaawardhigh relevance
NIH / NIAMS · SBIR phase I · $322K · posted 2026-09-01
Drug Repurposing for the Treatment of Staphylococcus aureus Bacteremiaawardhigh relevance
NIH / NIAID · STTR phase I · $296K · posted 2026-09-01
A New and Disruptive Gene Based Therapy for Atrial Fibrillationawardhigh relevance
NIH / NHLBI · SBIR phase II · $1M · posted 2026-09-01

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 135 → 121 → 224 → 171 → 103 new companies 2022 → 2026 · 92% aliveYC F26 live: 1 in this cluster, 2% of the batch (was 6% in S26)Since February, of 444 YC companies here: 5 acquired, 5 shut down, 41 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Enterprise
Business model: Marketplace
Path to 100x: Creates a new category
Market size: $100B+ market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: Revenue in 1-3 years
Technical depth: Deep tech: ML, hardware, bio
Go-to-market: Partners and channels
Moat: License or regulatory moat
Geography: US first
Regulation: Heavily regulated
Vibe: Boring business